Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company
Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company
Key Insights
关键见解
- Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable to their trading decisions
- A total of 22 investors have a majority stake in the company with 51% ownership
- Recent sales by insiders
- 鉴于机构持有该股的大量股份,爱德华兹生命科学的股价可能容易受到其交易决策的影响
- 共有22名投资者持有该公司的多数股权,所有权为51%
- 内部人士最近的销售额
Every investor in Edwards Lifesciences Corporation (NYSE:EW) should be aware of the most powerful shareholder groups. With 85% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
爱德华兹生命科学公司(纽约证券交易所代码:EW)的每位投资者都应该了解最强大的股东群体。机构拥有85%的股份,是公司的最大股份。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
鉴于他们拥有大量资金和研究能力,机构所有权往往具有很大的份量,尤其是对个人投资者而言。因此,将大量机构资金投资于公司通常被视为一种理想的特征。
Let's delve deeper into each type of owner of Edwards Lifesciences, beginning with the chart below.
让我们从下图开始,深入研究爱德华兹生命科学的每种类型的所有者。

What Does The Institutional Ownership Tell Us About Edwards Lifesciences?
关于爱德华兹生命科学,机构所有权告诉我们什么?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常用指数的回报进行比较。因此,他们通常会考虑收购包含在相关基准指数中的大型公司。
As you can see, institutional investors have a fair amount of stake in Edwards Lifesciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Edwards Lifesciences, (below). Of course, keep in mind that there are other factors to consider, too.
如你所见,机构投资者持有爱德华兹生命科学的大量股份。这意味着在这些机构工作的分析师已经看过这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。如果两个大型机构投资者试图同时抛售股票,股价大幅下跌的情况并不少见。因此,值得查看爱德华兹生命科学过去的收益轨迹(见下文)。当然,请记住,还有其他因素需要考虑。

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Edwards Lifesciences. Looking at our data, we can see that the largest shareholder is The Vanguard Group, Inc. with 11% of shares outstanding. For context, the second largest shareholder holds about 9.3% of the shares outstanding, followed by an ownership of 5.3% by the third-largest shareholder.
投资者应注意,机构实际上拥有公司一半以上的股份,因此它们可以共同行使巨大的权力。对冲基金在爱德华兹生命科学的股票不多。从我们的数据来看,我们可以看到最大的股东是Vanguard Group, Inc.,其已发行股份为11%。就背景而言,第二大股东持有约9.3%的已发行股份,其次是第三大股东持有5.3%的所有权。
After doing some more digging, we found that the top 22 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.
经过进一步的挖掘,我们发现前22名股东拥有该公司的总所有权为51%,这表明没有一个单一股东对公司拥有重大控制权。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
尽管研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解公众舆论也是有意义的。有合理数量的分析师报道该股,因此了解他们对未来的总体看法可能会很有用。
Insider Ownership Of Edwards Lifesciences
爱德华兹生命科学的内部所有权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
尽管内部人员的确切定义可能是主观的,但几乎所有人都认为董事会成员是内部人士。公司管理层对董事会的回答,董事会应代表股东的利益。值得注意的是,有时高层管理人员自己也在董事会中。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使得其他股东更难要求董事会对决策负责。
Our most recent data indicates that insiders own less than 1% of Edwards Lifesciences Corporation. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$399m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我们最新的数据显示,内部人士拥有爱德华兹生命科学公司不到1%的股份。由于它是一家大公司,我们只期望内部人士拥有其中的一小部分。但值得注意的是,他们拥有价值3.99亿美元的股票。看到至少有一部分内部所有权总是件好事,但可能值得检查一下这些内部人士是否一直在出售。
General Public Ownership
普通公有制
The general public, who are usually individual investors, hold a 14% stake in Edwards Lifesciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
公众通常是个人投资者,持有爱德华兹生命科学14%的股份。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
Next Steps:
后续步骤:
It's always worth thinking about the different groups who own shares in a company. But to understand Edwards Lifesciences better, we need to consider many other factors.
拥有公司股份的不同群体总是值得考虑的。但是,为了更好地了解爱德华兹生命科学,我们需要考虑许多其他因素。
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
我喜欢更深入地了解一家公司过去的表现。您可以免费访问这张包含过去收入、收入和现金流的交互式图表。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你像我一样,你可能需要考虑这家公司是增长还是萎缩。幸运的是,您可以查看这份免费报告,该报告显示了分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后日期的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。